Two Sigma Advisers’s Marker Therapeutics MRKR Stock Holding History

Two Sigma Advisers’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-33,980	Closed	-$150K	–	2803
2022 Q1	$150K	Sell	33,980 -27,090	-44%	-$155K	﹤0.01%	2433
2021 Q4	$580K	Sell	61,070 -26,760	-30%	-$355K	﹤0.01%	1849
2021 Q3	$1.48M	Sell	87,830 -47,630	-35%	-$976K	﹤0.01%	1412
2021 Q2	$3.78M	Buy	135,460 +121,090	+843%	+$3.19M	0.01%	992
2021 Q1	$322K	Buy	+14,370	New	+$329K	﹤0.01%	2194

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $153M AUM

AAM

AR Asset Management West Hollywood, California $546M AUM 24.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

MAA

Matrix Asset Advisors White Plains, New York $1.23B AUM 26.4% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Two Sigma Advisers's MRKR Position: Q2 2022 in Review

Two Sigma Advisers sold out of Marker Therapeutics (MRKR) in Q2 2022, closing a stake of 33,980 shares — an estimated $150K sold.

Two Sigma Advisers first reported a position in MRKR in Q1 2021 and held it in 5 quarters. The position peaked at $3.78M in Q2 2021. 48 funds tracked by Wall St. Rank hold MRKR as of Q2 2022.

Two Sigma Advisers reported no remaining Marker Therapeutics position as of Q2 2022 after selling out during the quarter.
Two Sigma Advisers sold 33,980 Marker Therapeutics shares in Q2 2022, an estimated $150K.
Two Sigma Advisers first reported a position in Marker Therapeutics in Q1 2021 and held it in 5 quarters.
Two Sigma Advisers's Marker Therapeutics position peaked at $3.78M in Q2 2021.
48 funds tracked by Wall St. Rank held Marker Therapeutics as of Q2 2022.

Based on Two Sigma Advisers's 13F filing for Q2 2022, filed 15 Aug 2022.